• Feedback
  • RIVM

Webbased Archive of RIVM Publications

Collection All
Listed communities

Webbased Archive of RIVM Publications > Articles and other publications by RIVM employees > Vaccines and Vaccination > Long-term protection against carriage of hepatitis B virus after infant vaccination.

Please use this identifier to cite or link to this item: http://hdl.handle.net/10029/6786
    Del.icio.us     LinkedIn     Citeulike     Connotea     Facebook     Stumble it!

Title: Long-term protection against carriage of hepatitis B virus after infant vaccination.
Authors: Sande, Marianne A B van der
Waight, P
Mendy, M
Rayco-Solon, P
Hutt, P
Fulford, T
Doherty, C
McConkey, S J
Jeffries, D
Hall, A J
Whittle, H C
Citation: J. Infect. Dis. 2006, 193(11):1528-35
Issue Date: 1-Jun-2006
URI: http://hdl.handle.net/10029/6786
DOI: 10.1086/503433
PubMed ID: 16652281
Abstract: BACKGROUND: Carriage of hepatitis B virus (HBV) is a major risk factor for liver cirrhosis and hepatocellular carcinoma. Infant vaccination has been effective in preventing horizontal transmission during early childhood. It is unknown whether protection is maintained into early adulthood. METHODS: In 1984, early childhood vaccination was introduced in 2 rural Gambian villages. In 2003, serological assessment of 81.5% of 1,350 eligible participants 1-24 years old was done, to determine vaccine efficacy against infection and carriage. RESULTS: Overall vaccine efficacy against infection and carriage was 83.4% (95% confidence interval [CI], 79.8%-86.6%) and 96.5% (85% CI, 93.9%-98.9%), respectively. Vaccine efficacy against infection was similar when restricted to primary responders (85.3%), but a significant effect of peak antibody concentration was found. Both vaccine efficacy and levels of hepatitis B surface antibody (anti-HBs) decreased with age, resulting in a vaccine efficacy against infection and carriage among 20-24-year-old participants of 70.9% (95% CI, 60.4%-80.5%) and 91.1% (95% CI, 75.8%-100%), respectively. Fifteen years after vaccination, fewer than half of the vaccinees had detectable anti-HBs. The prevalence of carriage in the unvaccinated population was similar to the prevalence 20 years earlier. CONCLUSIONS: HBV vaccination early during life can provide long-lasting protection against carriage, despite decreasing antibody levels. The role played by subclinical boosting and the necessity of a booster need to be evaluated.
Type: Article
Language: en
ISSN: 0022-1899
Appears in Collections:  Vaccines and Vaccination

Files in This Item:
File Description Size Format View/Open
vandersande.pdf220KbAdobe PDFThumbnail

Related articles on PubMed
Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages.
Whittle HC, Maine N, Pilkington J, Mendy M, Fortuin M, Bunn J, Allison L, Howard C, Hall A
1995 Apr 29
Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence.
van der Sande MA, Waight PA, Mendy M, Zaman S, Kaye S, Sam O, Kahn A, Jeffries D, Akum AA, Hall AJ, Bah E, McConkey SJ, Hainaut P, Whittle HC
2007 Aug 15
Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children.
Whittle H, Jaffar S, Wansbrough M, Mendy M, Dumpis U, Collinson A, Hall A
2002 Sep 14
Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation.
Fortuin M, Chotard J, Jack AD, Maine NP, Mendy M, Hall AJ, Inskip HM, George MO, Whittle HC
1993 May 1
See all 101 articles

All Items in WARP are protected by copyright, with all rights reserved, unless otherwise indicated.